Buerger Disease
An inflammatory disease of small/medium blood vessels in the limbs strongly linked to smoking, leading to tissue death and amputation.
Emergency Management: Infected, wet gangrene requires emergent broad-spectrum IV antibiotics (e.g., Piperacillin-Tazobactam 3.375 g IV q6h) and urgent surgical debridement or amputation to prevent systemic sepsis.
A non-atherosclerotic, segmental, inflammatory vascular disease that predominantly affects the small and medium-sized arteries and veins of the upper and lower extremities. It is strongly and almost exclusively associated with heavy tobacco use.
Detailed Overview
Buerger disease is characterized by a highly cellular, inflammatory thrombus with relative sparing of the blood vessel wall. Unlike atherosclerosis, the internal elastic lamina remains intact. It typically presents in young, heavy smokers with claudication of the feet or hands, progressing rapidly to ischemic rest pain, ischemic ulcerations, and gangrene requiring amputation if smoking is not halted.
Epidemiology & Demographics
Prevalence is highly variable; in North America, it accounts for <1% of patients with peripheral arterial disease. Most common in the Middle East, Far East, and Eastern Europe. Typically affects males between the ages of 20 and 45 years, though female incidence is rising.
Etiological Mechanism
The exact cause is unknown, but it is an autoimmune/inflammatory reaction triggered by components of tobacco. Tobacco exposure is absolutely essential for both disease initiation and progression.
Primary Causes
["Heavy cigarette smoking", "Chewing tobacco or cannabis use (rarely)"]
In the acute phase, a highly cellular thrombus forms in the lumen containing polymorphonuclear leukocytes, microabscesses, and multinucleated giant cells. The inflammation is transmural but preserves the internal elastic lamina. Over time, the thrombus organizes and recanalizes. Vasospasm and physical obstruction lead to profound distal tissue ischemia.
Diagnostic Criteria & Guidelines
Olin criteria: 1) Age < 45 years; 2) Current/recent history of tobacco use; 3) Presence of distal extremity ischemia (claudication, rest pain, ischemic ulcers, or gangrenes); 4) Exclusion of autoimmune diseases, hypercoagulable states, and diabetes; 5) Exclusion of proximal source of emboli; 6) Consistent angiographic findings in the clinically involved and noninvolved limbs.
Absolute, complete smoking cessation. No exceptions. Even nicotine replacement therapy must ultimately be stopped as nicotine itself may perpetuate the disease. Supportive care for ischemic digits including gentle debridement and non-adherent dressings.
Second-Line & Adjunctive Therapy
Intravenous Iloprost (a prostacyclin analog) can be used for patients with critical limb ischemia and rest pain to improve healing of ulcers while they cease smoking. Calcium channel blockers (Amlodipine 5-10 mg daily) can treat secondary Raynaud phenomenon.
Surgical & Procedural Management
Surgical revascularization (bypass) is typically not possible because the distal small target vessels are heavily diseased. Amputation (digital, transmetatarsal, or below-knee) is the definitive surgical treatment for frank gangrene or unremitting rest pain in patients who continue to smoke.
Patient Counseling & Advice
The patient must understand that continuing to smoke even a single cigarette a day will lead to the loss of their fingers and toes. If they stop smoking completely, the risk of major amputation drops to near zero.
Follow-Up & Monitoring Schedule
Monthly visits during the active phase to monitor wound healing and strictly verify smoking cessation via cotinine levels if necessary.
Preventive Strategies
Never starting tobacco use.
If the patient quits smoking completely, the disease halts, and amputation is rarely necessary (0-5%). If the patient continues smoking, the rate of major amputation is up to 40-50% over 5-10 years.